Biotech CEOs to Cassidy: We're already seeing the effects of FDA's staff cuts

Biopharma companies with pending applications at the FDA have "already encountered regulatory difficulties that we believe are the consequences of the FDA’s loss of experienced staff," more than 100 biotech and VC executives wrote to ...